What are our  “Cutting-Edge Biomedical Solutions” ? 

Integrated solutions to advanced challenges faced by biomedical researchers in nanomedicine, tissue engineering and regenerative medicine, diagnostic and medical device, that includes design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological point of view up to preclinical validation.

Due to the current pandemic outbreak of COVID-19, caused by the SARS-CoV-2 virus, knowledge about the virus characteristics and the development of its possible diagnostic, treatment and prophylactic devices and systems are high priority in all research institutions worldwide.

NANBIOSIS assigns high priority to the projects related to the SARS-CoV-2 virus offering preferential access. For that purpose, A “COVID-19 Rapid Access” call has been established, valid through the years 2020-22. Urgent procedure will be applied to review and admission of the proposals. 

Customized biomolecules production

Customized design and production services of biological molecules for Tissue Engineering, Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors by providing for applications such as:
− Therapeutic agents
− Targeting
− Surfaces functionalization: Tissue engineering/scaffolds & biosensors

Recombinant proteins
Antibodies and Haptens
Custom peptides and post modification
Oligonucleotides
Anti-peptide Antibodies
Protein-only nanomaterial platform for biomedical purposes

Nanomaterials

Supply nanomaterials for applications in Nanomedicine: therapy, drug delivery, contras agents (MRI, fluorescence) & theranostic

Nanoparticles
Pure active pharmaceutical ingredients with controlled nansotructure

Nanoconjugates & bioconjugates

Supply nanoconjugates for applications in Nanomedicine: therapy, contras agents (MRI) & theranostic)

Bioconjugation
Nanoconjugation
Micro and nanoencapsulation

Nanomedicines Preclinical validation

Preclinical characterization of nanomedicines including physicochemical properties, in vitro and in vivo biological properties (immunology, toxicology an efficacy with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions

Complete cascade characterization
Physicochemical characterization
In vitro characterization
In vivo characterization

In vitro Diagnostic

Development of prototypes and biosensing devices for diagnostic, production of bioreceptor against identified biomarkers an detection of biomarkers for diagnostic, follow-up and prognostic of diseases by NMR spectroscopies in biofluids and tissues.

Development and validation of biosensor
Anti-peptide Antibodies
Devices
Quatintifaction of Biomarker by NMR

In vivo diagnostic

In vivo validation of contrast agents and development of nanoconjugates as contrast agents for MRI and fluorescence.

Nanoparticles
Contrast Agents for MRI & OTC
Validation of NPs for glioma
Validation of Contrast Agents for MRI
Nanocojugates for fluorescence
Nanocojugates for MRI

3D bioprinting

Design and production of scaffolds for tissue engineering

Scaffolds
Functionalized scaffolds

Biomaterials preclinical characterization

Preclinical validation of biomaterials including surface and mechanical characterization and in vitro and in vivo biological properties with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions

Preclinical validation
Surface and mechanical characterization
Adhesion of bateria: biofilms
Biocampatibility

Validation of Medical devices

In vivo Validation of medical devices for determined applications in different animal models